Vaccitech rebrands as Barinthus, plans to present data at AASLD meeting
Vaccitech said that it has rebranded at Barinthus Biotherapeutics to reflect its expansion beyond developing vaccines. Barinthus shares will begin trading on Nasdaq under the symbol BRNS on Tuesday, Nov. 7. The company added that it plans to present Phase 2 data on its drug candidate VTP-300 in the treatment of patients with chronic hepatitis B at The American Association for the Study of Liver Diseases, or AASLD, to be held Nov. 10-14 in Boston. More on Vaccitech Vaccitech surges despite Morgan Stanley downgrade Seeking Alpha’s Quant Rating on Vaccitech Historical earnings data for Vaccitech Financial information for Vaccitech